Kromatid

About Kromatid

Kromatid specializes in genomics and chromosomal analysis, providing products and services to the cell and gene therapy, and radiation biodosimetry markets. The company was founded in 2007 by a team with expertise in chromosome biology and genomics. Its headquarters are in Longmont, Colorado, United States.

The core of Kromatid's offering is its proprietary directional Genomic Hybridization (dGH) platform, a single-cell, whole-genome assay technology used for chromosome analysis. This technology allows for the detection of structural genomic variations and provides insights into chromosomal rearrangements that might be missed by other methods. Their services include measuring genotoxicity, assessing the on-target and off-target effects of gene-editing systems like CRISPR, and tracking the integrity of engineered cells. For the radiation biodosimetry market, Kromatid offers solutions to measure individual absorbed radiation doses by analyzing chromosomal inversions, which is crucial for military personnel and first responders.

The company serves a range of clients, including preclinical and clinical stage gene therapy companies, large pharmaceutical firms, and government entities. Its business model revolves around providing fee-for-service projects and selling dGH-based products. This includes dGH in-vitro diagnostic assay services and custom assay development to help clients de-risk their gene therapy programs and ensure the stability of their cell lines.